Accepted at 10:37 p.m. Dec, 19, 2024 by mohannadkh10
Author: mohannadkh10
Related Note: 1488768061994 1
Rationale for change

I just keep forgetting that dabigatran is a DOAC
Source: AMBOSS - https://next.amboss.com/us/article/Tm06Ug?q=dabigatran#Z6473b5ec0e24b459b417c9555ea6689c

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Picmonic
Empty field
Pixorize
Empty field
Physeo
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::04_Direct_coagulation_factor_inhibitors::*Direct_Thrombin_Inhibitors #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::01_Heparin,_LMWH,_fondaparinux,_direct_thrombin_inhibitors,_Xa_inhibitors #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::02_DirectThrombinInhibitors_DirectFactorXaInhibitors #AK_Step1_v12::#Physeo::^physeo_image_update #PANCE::EOR::Family_med #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants #AK_Step1_v12::#AMBOSS::pQaLC4 #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs::Extra #AK_Step1_v12::#AMBOSS #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents